Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Assess the Feasibility of Non-invasive Dried Blood Sampling for Assessment of EDG-5506 Concentrations

NCT05492734 is registered in ClinicalTrials.gov with Edgewise Therapeutics, Inc. as lead sponsor.

NCT NCT05492734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05492734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Assess the Feasibility of Non-invasive Dried Blood Sampling for Assessment of EDG-5506 Concentrations
Lead sponsor
Edgewise Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 12, 2022
Completion date
August 19, 2022
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

muscular dystrophies